Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs MaxLinear Inc. Common Stock (MXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs MaxLinear Inc. Common Stock — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while MaxLinear Inc. Common Stock trades at $76.13 (market cap $8.04B). The key difference: MaxLinear Inc. Common Stock is far larger — about 8.3× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is more actively traded (4,325,710 versus 2,554,408). Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and MaxLinear Inc. Common Stock for 3 Days on average.
| MRVI | MXL | |
|---|---|---|
Market Cap | $972.90M | $8.04B |
Volume | 4,325,710 | 2,554,408 |
Sector | Health | Technology |
52-Week High | $9.00 | $128.03 |
52-Week Low | $2.83 | $13.05 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $1.08B | $8.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
MaxLinear (MXL) trades at $88.64, down 0.39% on the day, with strong technical momentum indicated by bullish moving averages and key support at $87. The company shows impressive revenue growth with Q2 2026 EPS beating expectations at $0.35 versus $0.33, though profitability remains challenged with a -18.24% net income margin. Recent AI-focused product launches like Topaz™ PON chips and strong infrastructure demand position MXL for continued growth.
MXL presents a compelling growth story driven by AI infrastructure demand, with analyst consensus at Buy (64.7%) and $91.67 price target offering 3.4% upside. However, negative profitability metrics and cash flow concerns require careful monitoring. The stock's 50.7% September surge (Motley Fool, Oct 2) reflects optimism, but execution risks and valuation premium warrant cautious optimism for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About MaxLinear Inc. Common Stock
MaxLinear develops analog and mixed-signal semiconductors for connectivity, communications, industrial, and data center applications.
Read more on MXL →
